Business Context and Reporting Period
Company: ReWalk Robotics Ltd. (trading as Lifeward Ltd.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: Lifeward designs and commercializes medical devices for physical rehabilitation, including the ReWalk exoskeletons for spinal cord injury, the ReStore exo-suit for stroke recovery, and AlterG anti-gravity systems acquired in August 2023. The company rebranded from ReWalk Robotics to Lifeward in January 2024.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenues | $6,707 | $1,337 | $11,990 | $2,567 |
| Gross Profit | $2,757 | $576 | $4,152 | $1,147 |
| Gross Margin | 41.1% | 43.1% | 34.6% | 44.7% |
| Operating Loss | $(4,443) | $(5,158) | $(10,945) | $(9,533) |
| Net Loss | $(4,304) | $(4,642) | $(10,580) | $(8,963) |
| Net Loss Per Share (Basic/Diluted) | $(0.50) | $(0.55) | $(1.23) | $(1.05) |
| Cash and Cash Equivalents (End of Period) | $15,131 (as of June 30, 2024) | |||
| Operating Cash Flow (YTD) | $(13,290) | $(8,739) |
Liquidity: The company reported $15.1 million in cash and cash equivalents as of June 30, 2024. Management states it has sufficient funds to support operations for more than 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 401% in Q2 2024 compared to Q2 2023. This was driven by the inclusion of AlterG revenue ($3.6 million in Q2) and increased sales of ReWalk Personal exoskeletons due to expanded Medicare coverage.
- Operating Expenses: Total operating expenses increased to $7.2 million in Q2 2024 from $5.7 million in Q2 2023. Sales and marketing expenses rose 76% due to higher headcount from the AlterG acquisition and increased promotional spending. Research and development expenses increased 48% due to new product development investments.
- Gross Margin Compression: Gross margin for the six months ended June 30, 2024, was 34.6%, down from 44.7% in the prior year. This decline was attributed to lower AlterG sales volume in Q1 affecting cost absorption and amortization of intangible assets ($0.8 million included in YTD gross profit).
- Share Structure: A one-for-seven reverse share split became effective on March 15, 2024. All share and per-share data in the filing are retroactively adjusted.
Guidance, Outlook, and Risks
- Medicare Reimbursement: The company highlighted that the CMS Home Health Rule and Medicare pricing ($91,032 lump sum) are now fully functional, with widespread approvals and payments beginning for 2023 and first-half 2024 submissions.
- Product Pipeline: In June 2024, the company launched the AlterG NEO product line and submitted a 510(k) premarket notification for the ReWalk 7 Personal Exoskeleton to the FDA.
- Capital Needs: The company expects to incur future net losses and will need to raise additional cash to fund operations until profitability is achieved. It intends to fund operations through cash on hand, private/public offerings, or warrant exercises.
- Legal Proceedings: Creative Value Capital Limited Partnership (CVC) initiated litigation seeking to add two director candidates to the agenda for the September 4, 2024, Annual Meeting. The company rejected the request, and a court hearing is scheduled for August 26, 2024.
- Geopolitical Risks: The filing notes risks related to the ongoing war between Israel and Hamas and tensions between China and Taiwan, which could disrupt operations or supply chains.
Investor Verification Checklist
- Medicare Adoption Rate: Verify the actual volume of ReWalk units sold under the new Medicare reimbursement pathway and the speed of payment processing from CMS.
- AlterG Integration: Assess whether AlterG revenue growth is sufficient to trigger the $4.0 million potential earnout payments and if the integration is delivering expected synergies.
- Cash Burn Rate: Monitor the negative operating cash flow (YTD $13.3 million) against the current cash balance ($15.1 million) to determine the runway before additional capital raises are required.
- Activist Litigation: Track the outcome of the CVC lawsuit regarding the board election, as a proxy contest could be costly and disruptive.
- Supply Chain Resilience: Confirm the impact of the conflict in Israel on manufacturing and logistics, given the company's reliance on specific contract manufacturers and inventory safety stock strategies.